NCT01029743 - Xarelto Regulatory Post-Marketing Surveillance | Biotech Hunter

Enrollment

3,388

Participants

Timeline

Start Date

December 31, 2009

Primary Completion Date

March 31, 2015

Study Completion Date

January 31, 2016

Conditions

Venous Thromboembolism

Interventions

DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended

DRUG

Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)

Daily dose, dosage frequency and duration will be decided by physicians

Trial Locations (1)

Unknown

Many Locations